insulin lispro

别名: 赖脯人胰岛素; 28B-L-赖氨酸-29B-L-脯氨酸人胰岛素; 赖脯胰岛素;赖脯胰岛素 USP标准品
目录号: V41694 纯度: ≥98%
赖脯胰岛素是一种重组人胰岛素类似物,也是三种速效胰岛素类似物之一。
insulin lispro CAS号: 133107-64-9
产品类别: New3
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
1mg
Other Sizes
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
产品描述
赖脯胰岛素是一种重组人胰岛素类似物,也是三种速效胰岛素类似物之一。赖脯胰岛素可用于糖尿病高血糖的研究/学习。
生物活性&实验参考方法
参考文献

[1]. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs. 2007;67(3):407-34.

其他信息
Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
See also: Insulin Lispro (annotation moved to).
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C158H234N40O42S2.C99H155N25O35S4
分子量
5813.61785999995
精确质量
5811.691
CAS号
133107-64-9
PubChem CID
16132438
外观&性状
White to off-white solid powder
tPSA
2310
氢键供体(HBD)数目
84
氢键受体(HBA)数目
89
可旋转键数目(RBC)
185
重原子数目
405
分子复杂度/Complexity
13000
定义原子立体中心数目
52
SMILES
[H]/N=C(/NCCC[C@@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(=O)O)[C@H](O)C)=O)CCC1)=O)CCCCN)=O)[C@H](O)C)=O)CC1=CC=C(O)C=C1)=O)CC1=CC=CC=C1)=O)CC1=CC=CC=C1)=O)=O)NC([C@@H](NC(CNC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)N)=O)=O)CC(=O)N)=O)CCC(=O)N)=O)CC1N=CNC=1)=O)CC(C)C)=O)CS)=O)=O)CO)=O)CC1N=CNC=1)=O)CC(C)C)=O)=O)CCC(=O)O)=O)C)=O)CC(C)C)=O)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)=O)CS)=O)=O)CCC(=O)O)=O)\N.CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CC(=O)N)=O)CS)=O)CC1=CC=C(O)C=C1)=O)CC(=O)N)=O)CCC(=O)O)=O)CC(C)C)=O)CCC(=O)N)=O)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)CO)=O)CS)=O)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@H]([C@H](CC)C)NC(CN)=O)=O)=O)CCC(=O)O)=O)CCC(=O)N)=O)CS)=O)CS)=O)=O)CO)=O)C
InChi Key
WNRQPCUGRUFHED-DETKDSODSA-N
InChi Code
InChI=1S/C158H234N40O42S2.C99H155N25O35S4/c1-79(2)57-104(181-131(213)86(15)173-136(218)102(50-53-125(211)212)179-152(234)127(84(11)12)194-148(230)107(60-82(7)8)184-145(227)113(67-95-70-166-78-172-95)189-150(232)115(74-199)176-123(208)73-170-134(216)116(75-241)191-140(222)105(58-80(3)4)182-144(226)112(66-94-69-165-77-171-94)188-138(220)101(48-51-119(161)204)178-146(228)114(68-120(162)205)190-153(235)126(83(9)10)193-132(214)98(160)61-89-31-21-18-22-32-89)139(221)185-110(64-92-40-44-96(202)45-41-92)142(224)183-106(59-81(5)6)147(229)195-128(85(13)14)154(236)192-117(76-242)135(217)169-71-121(206)174-100(49-52-124(209)210)137(219)177-99(38-29-55-167-158(163)164)133(215)168-72-122(207)175-108(62-90-33-23-19-24-34-90)141(223)186-109(63-91-35-25-20-26-36-91)143(225)187-111(65-93-42-46-97(203)47-43-93)149(231)196-129(87(16)200)155(237)180-103(37-27-28-54-159)156(238)198-56-30-39-118(198)151(233)197-130(88(17)201)157(239)240;1-12-46(9)77(121-73(134)36-100)97(156)122-76(45(7)8)95(154)108-56(25-29-75(137)138)80(139)105-54(23-27-70(102)131)83(142)117-66(40-161)93(152)119-68(42-163)94(153)124-79(48(11)127)98(157)116-64(38-126)90(149)123-78(47(10)13-2)96(155)120-67(41-162)92(151)115-63(37-125)89(148)110-58(31-44(5)6)85(144)111-59(32-49-14-18-51(128)19-15-49)86(145)106-53(22-26-69(101)130)81(140)109-57(30-43(3)4)84(143)107-55(24-28-74(135)136)82(141)113-61(34-71(103)132)88(147)112-60(33-50-16-20-52(129)21-17-50)87(146)118-65(39-160)91(150)114-62(99(158)159)35-72(104)133/h18-26,31-36,40-47,69-70,77-88,98-118,126-130,199-203,241-242H,27-30,37-39,48-68,71-76,159-160H2,1-17H3,(H2,161,204)(H2,162,205)(H,165,171)(H,166,172)(H,168,215)(H,169,217)(H,170,216)(H,173,218)(H,174,206)(H,175,207)(H,176,208)(H,177,219)(H,178,228)(H,179,234)(H,180,237)(H,181,213)(H,182,226)(H,183,224)(H,184,227)(H,185,221)(H,186,223)(H,187,225)(H,188,220)(H,189,232)(H,190,235)(H,191,222)(H,192,236)(H,193,214)(H,194,230)(H,195,229)(H,196,231)(H,197,233)(H,209,210)(H,211,212)(H,239,240)(H4,163,164,167);14-21,43-48,53-68,76-79,125-129,160-163H,12-13,22-42,100H2,1-11H3,(H2,101,130)(H2,102,131)(H2,103,132)(H2,104,133)(H,105,139)(H,106,145)(H,107,143)(H,108,154)(H,109,140)(H,110,148)(H,111,144)(H,112,147)(H,113,141)(H,114,150)(H,115,151)(H,116,157)(H,117,142)(H,118,146)(H,119,152)(H,120,155)(H,121,134)(H,122,156)(H,123,149)(H,124,153)(H,135,136)(H,137,138)(H,158,159)/t86-,87+,88+,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,126-,127-,128-,129-,130-;46-,47-,48+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-,77-,78-,79-/m00/s1
化学名
(4S)-4-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R)-2-[[(2R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[[(2R)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid;(4S)-4-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[(2S)-2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方,主要用于溶解难溶或不溶于水的产品(水溶度<1 mg/mL)。 建议您先取少量样品进行尝试,如该配方可行,再根据实验需求增加样品量。

注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80: Saline = 10 : 5 : 85 (如: 100 μL DMSO 50 μL Tween 80 850 μL Saline)
*生理盐水/Saline的制备:将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中,得到澄清溶液。
注射用配方 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL DMSO 400 μL PEG300 50 μL Tween 80 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如: 100 μL DMSO 900 μL Corn oil)
示例: 注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液,加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如:100 μL DMSO 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备(4°C,储存1周):将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中,得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如: 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精) 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如: 50 μL DMSO 100 μL PEG300 200 μL Castor oil 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (如: 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如: 100 μL EtOH 900 μL Corn oil)
注射用配方 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (如: 100 μL EtOH 400 μL PEG300 50 μL Tween 80 450 μL Saline)


口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中,得到0.5%CMC-Na澄清溶液;然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中,得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合


注意: 以上为较为常见方法,仅供参考, InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型,对于某些尚未有文献报道溶解方法的化合物,需通过前期实验来确定(建议先取少量样品进行尝试),包括产品的溶解情况、梯度设置、动物的耐受性等。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 0.1720 mL 0.8600 mL 1.7201 mL
5 mM 0.0344 mL 0.1720 mL 0.3440 mL
10 mM 0.0172 mL 0.0860 mL 0.1720 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
CTID: NCT05893797
Phase: N/A    Status: Completed
Date: 2024-11-29
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
CTID: NCT05462756
Phase: Phase 3    Status: Completed
Date: 2024-08-22
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT06280703
Phase: Phase 1    Status: Recruiting
Date: 2024-05-31
Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique
CTID: NCT03229850
Phase: N/A    Status: Suspended
Date: 2024-05-08
Simplified Insulin Regimen for the Elderly
CTID: NCT03660553
Phase: Phase 4    Status: Terminated
Date: 2023-12-12
View More

Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
CTID: NCT04019821
Phase: Phase 4    Status: Completed
Date: 2023-11-30


A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
CTID: NCT04537923
Phase: Phase 3    Status: Completed
Date: 2023-11-02
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
CTID: NCT05834868
Phase: Phase 3    Status: Recruiting
Date: 2023-04-28
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
CTID: NCT03952130
Phase: Phase 3    Status: Completed
Date: 2023-02-08
Effects of Insulin on Hypotension and Sarcopenia
CTID: NCT03248271
Phase:    Status: Withdrawn
Date: 2023-01-12
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
CTID: NCT04816890
Phase: Phase 2    Status: Completed
Date: 2022-06-24
Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
CTID: NCT01613807
Phase: Phase 4    Status: Completed
Date: 2022-06-08
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
CTID: NCT03952143
Phase: Phase 3    Status: Completed
Date: 2022-02-08
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
CTID: NCT03740919
Phase: Phase 3    Status: Completed
Date: 2022-01-24
A Study of LY900014 in Healthy Chinese Participants
CTID: NCT04049123
Phase: Phase 1    Status: Completed
Date: 2021-11-16
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
CTID: NCT04276207
Phase: Phase 1    Status: Completed
Date: 2021-08-25
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus
CTID: NCT03338023
Phase: Phase 3    Status: Completed
Date: 2021-03-29
Feasibility Trial Testing the Bionic Pancreas With ZP4207
CTID: NCT02971228
Phase: Phase 2    Status: Completed
Date: 2021-03-23
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
CTID: NCT03830281
Phase: Phase 3    Status: Completed
Date: 2021-01-22
Comparison of Insulins Aspart and Lispro in Insulin Pumps
CTID: NCT00461331
Phase: Phase 4    Status: Completed
Date: 2021-01-08
A Study of LY900014 in a Medtronic Pump
CTID: NCT03760640
Phase: Phase 2    Status: Completed
Date: 2020-10-29
A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus
CTID: NCT04161976
Phase: Phase 1    Status: Completed
Date: 2020-08-05
A Study of LY900014 in Participants With Type 1 Diabetes Mellitus
CTID: NCT03465878
Phase: Phase 1    Status: Completed
Date: 2020-06-18
A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy
CTID: NCT02703337
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
CTID: NCT02703350
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
CTID: NCT02703324
Phase: Phase 1    Status: Completed
Date: 2020-06-17
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
CTID: NCT03341312
Phase: Phase 1    Status: Completed
Date: 2020-06-09
A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
CTID: NCT02770521
Phase: Phase 1    Status: Completed
Date: 2020-06-04
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
CTID: NCT03305822
Phase: Phase 1    Status: Completed
Date: 2020-05-27
A Study of a New LY900014 Formulation in Healthy Participants
CTID: NCT02525744
Phase: Phase 1    Status: Completed
Date: 2020-05-19
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
CTID: NCT03341299
Phase: Phase 1    Status: Completed
Date: 2020-05-14
A Study of LY900014 Formulations in Healthy Participants
CTID: NCT02317575
Phase: Phase 1    Status: Completed
Date: 2020-05-13
A Study of Various Formulations of LY900014 in Healthy Participants
CTID: NCT02636361
Phase: Phase 1    Status: Completed
Date: 2020-05-13
A Study of LY900014 in Participants With Type 1 Diabetes
CTID: NCT03214367
Phase: Phase 3    Status: Completed
Date: 2020-05-01
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
CTID: NCT03407118
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump
CTID: NCT03056456
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants
CTID: NCT03286751
Phase: Phase 1    Status: Completed
Date: 2020-05-01
A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus
CTID: NCT03166124
Phase: Phase 1    Status: Completed
Date: 2020-04-30
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
CTID: NCT03449433
Phase: Phase 1    Status: Completed
Date: 2020-04-30
A Study of LY900014 Formulation in Healthy Participants
CTID: NCT02942654
Phase: Phase 1    Status: Completed
Date: 2020-04-27
A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes
CTID: NCT03214380
Phase: Phase 3    Status: Completed
Date: 2020-03-27
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
CTID: NCT04124302
Phase: Phase 4    Status: Unknown status
Date: 2019-10-11
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
CTID: NCT03433677
Phase: Phase 3    Status: Completed
Date: 2019-10-08
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
CTID: NCT04100473
Phase: Phase 2    Status: Completed
Date: 2019-09-24
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
CTID: NCT01621178
Phase: Phase 3    Status: Completed
Date: 2019-09-19
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
CTID: NCT03307512
Phase: Phase 2    Status: Terminated
Date: 2019-09-13
Assessment of Mealtime Bolus Insulin Behavior
CTID: NCT03368807
Phase:    Status: Completed
Date: 2019-08-02
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes
CTID: NCT03890003
Phase: N/A    Status: Completed
Date: 2019-06-05
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
CTID: NCT03849612
Phase: N/A    Status: Completed
Date: 2019-04-25
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges
CTID: NCT03848767
Phase: N/A    Status: Completed
Date: 2019-04-23
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
CTID: NCT02152384
Phase: Phase 1    Status: Completed
Date: 2019-03-01
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
CTID: NCT01194245
Phase: Phase 2    Status: Completed
Date: 2019-02-26
Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase
CTID: NCT01526733
Phase: Phase 4    Status: Completed
Date: 2019-02-26
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)
CTID: NCT03743285
Phase: N/A    Status: Completed
Date: 2019-02-19
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT01848990
Phase: Phase 4    Status: Completed
Date: 2018-11-07
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
CTID: NCT02197520
Phase: Phase 1    Status: Completed
Date: 2018-11-01
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
CTID: NCT03682640
Phase: Phase 2    Status: Unknown status
Date: 2018-09-24
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
CTID: NCT00803972
Phase: Phase 1    Status: Completed
Date: 2018-08-15
Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)
CTID: NCT02794155
Phase: Phase 2    Status: Completed
Date: 2018-07-31
A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects
CTID: NCT03604575
Phase: N/A    Status: Completed
Date: 2018-07-27
Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes
CTID: NCT03509324
Phase: Phase 4    Status: Completed
Date: 2018-04-26
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
CTID: NCT01792284
Phase: Phase 3    Status: Completed
Date: 2018-04-20
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
CTID: NCT01662921
Phase: Phase 2    Status: Completed
Date: 2018-04-18
A Study in Participants With Type 2 Diabetes Mellitus
CTID: NCT01468987
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study in Participants With Type 1 Diabetes Mellitus
CTID: NCT01481779
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study in Participants With Type I Diabetes Mellitus
CTID: NCT01454284
Phase: Phase 3    Status: Completed
Date: 2018-04-17
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
CTID: NCT03367390
Phase: Phase 1    Status: Completed
Date: 2018-03-15
Normal Versus Dual Wave Insulin Bolus for High-protein Food
CTID: NCT02276859
Phase: Phase 4    Status: Completed
Date: 2018-01-31
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients
CTID: NCT01035801
Phase: Phase 1    Status: Terminated
Date: 2018-01-23
A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy
CTID: NCT02623452
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy
CTID: NCT02623465
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
CTID: NCT02623478
Phase: Phase 1    Status: Withdrawn
Date: 2017-07-13
Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus
CTID: NCT02470637
Phase: Phase 1    Status: Completed
Date: 2017-04-13
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
CTID: NCT00097071
Phase: Phase 3    Status: Completed
Date: 2016-12-22
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
CTID: NCT00071448
Phase: Phase 3    Status: Completed
Date: 2016-12-22
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
CTID: NCT02739906
Phase: Phase 1/Phase 2    Status: Completed
Date: 2016-08-18
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
CTID: NCT02685449
Phase: Phase 4    Status: Unknown status
Date: 2016-07-29
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
CTID: NCT00115570
Phase: Phase 3    Status: Completed
Date: 2016-05-20
Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion
CTID: NCT02603510
Phase: Phase 1    Status: Completed
Date: 2016-05-19
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
CTID: NCT02526810
Phase: Phase 4    Status: Unknown status
Date: 2015-08-20
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
CTID: NCT00849576
Phase: Phase 3    Status: Completed
Date: 2015-08-03
A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus
CTID: NCT01235039
Phase: Phase 1/Phase 2    Status: Completed
Date: 2015-07-29
A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants
CTID: NCT02111083
Phase: Phase 1    Status: Completed
Date: 2015-05-21
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
CTID: NCT00960661
Phase: Phase 3    Status: Completed
Date: 2015-04-07
Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients
CTID: NCT01776788
Phase: Phase 4    Status: Completed
Date: 2015-03-10
A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1
CTID: NCT02221323
Phase: Phase 2    Status: Completed
Date: 2014-12-30
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
CTID: NCT02273258
Phase: Phase 1    Status: Completed
Date: 2014-10-23
A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants
CTID: NCT01871493
Phase: Phase 1    Status: Completed
Date: 2014-10-21
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
CTID: NCT00700622
Phase: Phase 3    Status: Terminated
Date: 2014-10-16
A Study in Adults With Type 1 Diabetes
CTID: NCT01421147
Phase: Phase 3    Status: Completed
Da
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2019-10-23
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Completed
Date: 2019-03-29
I8B MC ITRO
CTID: null
Phase: Phase 3    Status: Completed
Date: 2019-03-18
A Randomized, Open-Label, 4-Period Cross-Over Study to Investigate the Inter- and Intra-subject Variability of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-11-27
A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-11-27
A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare
CTID: null
Phase: Phase 3    Status: Ongoing, Prematurely Ended
Date: 2018-10-24
A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-05-16
Protocol I8B-MC-ITSI
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-12-27
Evaluation of different algorithms for the calculation of the prandial insulin dose, considering the fat and protein content of the meal - Effects on postprandial glucose in type 1 diabetes patients with insulin pump therapy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-08-01
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-08-01
Protocol I8B-MC-ITRN
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-06-07
Impact on oxidative stress of novel analogues of insulin in people with type 1 diabetes. Low- intervention clinical trial. Ineox Study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-11-03
A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF THE ACUTE ADMINISTRATION OF THE SGLT-2 INHIBITOR CANAGLIFLOZIN ON CONTERREGULATORY RESPONSE TO INSULIN-INDUCED HYPOGLYCEMIA
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2016-10-27
Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-02-11
Blood glucose control with BC222 insulin lispro compared to insulin lispro (Humalog®) after ingestion of a standardised meal.
CTID: null
Phase: Phase 2    Status: Completed
Date: 2015-01-06
Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-11-19
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Period
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-11-12
A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-09-15
A double-blinded, randomised, three-period crossover euglycaemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of BC222 human insulin, human insulin (Huminsulin® Normal) and insulin lispro (Humalog®) in subjects with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-07-07
A double-blinded, randomised, four -period crossover euglycemic clamp trial investigating the dose-response and dose-exposure relationship of BC222 insulin lispro in three different doses in subjects with type 1 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2014-05-12
Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects with Type 2 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-09-24
Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects with Type 1 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2013-03-28
Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protocol in Renal Transplant Recipients Receiving a Tacrolimus-based Immunosuppression
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-01-14
An open, single-centre, non-controlled feasibility study using a softwarealgorithm based insulin therapy to control blood glucose in type 1 diabetic patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-01-07
Protocol I2R-MC-BIAN (a)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-03-05
Efficacy and mechanisms of a short course of intensified insulin treatment on remission or responsiveness to oral therapy in type 2 diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-03-01
Protocol I2R-MC-BIAM
CTID: null
Phase: Phase 3    Status: Completed
Date: 2012-01-24
Protocol I2R-MC-BIAO
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-12-02
A Prospective, Randomized, Open-Label Comparison of a
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-09-12
Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone
CTID: null
Phase: Phase 4    Status: Completed
Date: 2011-02-07
A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-09-09
The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-06-16
A single center, open-label, randomized study examining the glycemic effects of intra-dermal vs. subcutaneous bolus dosing of insulin lispro in patients with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2010-04-06
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus
CTID: null
Phase: Phase 3    Status: Completed
Date: 2010-01-29
Prevention of Recurrent Severe Hypoglycaemia: a Definitive RCT Comparing Optimised MDI and CSII with or without Adjunctive Real-time Continuous Glucose Monitoring.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-01-28
A mono-center, open label, randomised 2-period crossover study to compare the pharmacokinetics and pharmacodynamics of continuous insulin infusion administered either intradermally or subcutaneously in subjects with type 1 diabetes mellitus
CTID: null
Phase: Phase 2    Status: Completed
Date: 2009-12-23
A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) vs. Conventional Pen without Memory Function
CTID: null
Phase: Phase 4    Status: Completed
Date: 2009-09-11
A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 compared to VIAject™25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 1, Phase 2    Status: Completed
Date: 2009-07-10
A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 Diabetes who were previously treated by basal insulin Glargine with either Metformin or Metformin and Sulfonylurea
CTID: null
Phase: Phase 3    Status: Completed
Date: 2009-06-18
Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patients
CTID: null
Phase: Phase 3    Status: Completed
Date: 2008-04-22
A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-02-13
ESTUDIO COMPARATIVO DEL TRATAMIENTO CON BOMBA DE INSULINA SUBCUTANEA, INSULINA GLARGINA E INSULINA NPH EN NIÑOS DIABÉTICOS DE 0 A 6 AÑOS DE EDAD
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2008-02-01
Comparación de un régimen de insulina lispro premezclada (proporción baja, 25/75; y proporción media, 50/50) con un régimen de inyecciones separadas de insulina basal y en bolos, en pacientes con diabetes tipo 2 que consumen un desayuno ligero y presentan un control glucémico insuficiente con tratamiento oral
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-01-25
Comparison of Technosphere®/Insulin, Insulin Lispro and Exubera® Effect on Endogenous Glucose Production After a Meal Challenge and During a Euglycemic Glucose Clamp Procedure in Subjects with Type 2 Diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-12-27
A mono center, open-label glucose clamp study examining the metabolic effect of the frequency of insulin infusion intervals for basal insulin infusion in patients with type 1 diabetes
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-12-13
Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-11-13
A mono center, open-label, randomized study examining the effects of intra-dermal vs. subcutaneous application of regular human insulin or rapid-acting insulin analogue on postprandial glycemic excursions in patients with type 1 diabetes
CTID: null
Phase: Phase 2    Status: Completed
Date: 2007-09-14
Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medicaciones antidiabéticas
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-08-03
-----------------------

相关产品
联系我们